J Moreau - Dr Reddys Non-Executive Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:4em;padding-top: 25px;;'>DR</div>
RDY -- USA Stock  

USD 43.08  2.92  7.27%

Dr. J. P. Moreau is NonExecutive Independent Director of Dr. Reddy Laboratories Ltd May 2007. Dr. J P Moreau joined the Companys Board in 2007. He founded Biomeasure Incorporated based near Boston and was its President and CEO. Prior to that he was working as Executive VicePresident and Chief Scientific Officer of the IPSEN Group and was responsible for the Groups Discovery and Innovation with facilities in Paris London Barcelona and Boston. He was VicePresident Research from April 1994 and was a member of the Executive Committee of IPSEN Group since that date. He has published over 50 articles in scientific journals and has more than 30 patents to his name. He is a regular speaker at scientific conferences and a member of Nitto Denko Scientific Advisory Board. Dr. Moreau was also responsible for establishing Kinerton Limited in Ireland in March 1989 a wholesale manufacturer of therapeutic peptides. Dr. Moreau is also on the Board of Mulleris Therapeutics Inc. USA and ChondioThera Inc. USA
Age: 64  Director Since 2007  Ph.D    
91 40 4900 2900  http://www.drreddys.com
Moreau has a degree in Chemistry from the University of Orleans and a D.Sc. in biochemistry. He has also conducted postdoctorate research at the ?cole Polytechnique.

Management Efficiency

The company has Return on Asset of 7.9 % which means that on every $100 spent on asset it made $7.9 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.39 % implying that it generated $11.39 on every 100 dollars invested.
The company has 811.73 M in debt with debt to equity (D/E) ratio of 10.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.77 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


Christine PoonRegeneron Pharmaceuticals
Yuchun LeeVertex Pharmaceuticals Incorpor
Rolf ClassonPerrigo Company Plc
Gregory NordenZoetis
Yingqi XiaOrigin Agritech Limited
Marc TessierLavigneRegeneron Pharmaceuticals
Anthony ColesRegeneron Pharmaceuticals
William YoungVertex Pharmaceuticals Incorpor
Larry CordellOrigin Agritech Limited
Michael TrimbleOrigin Agritech Limited
Huda ZoghbiRegeneron Pharmaceuticals
Alan GarberVertex Pharmaceuticals Incorpor
George SingRegeneron Pharmaceuticals
Linda RhodesZoetis
Margaret McGlynnVertex Pharmaceuticals Incorpor
Lloyd CarneyVertex Pharmaceuticals Incorpor
Bruce SachsVertex Pharmaceuticals Incorpor
Laurie BrlasPerrigo Company Plc
Theodore SamuelsPerrigo Company Plc
Michael BrownRegeneron Pharmaceuticals
Gary KunklePerrigo Company Plc

Company Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing DirectorView
MARC KIKUCHI, Chief Executive Officer, North America GenericsView
Hans Hasler, Additional Independent DirectorView
Leo Puri, Non-Executive Independent DirectorView
Sandeep Poddar, Compliance Officer, Company SecretaryView
Satish Reddy, Co-Chairman of the BoardView
Kedar Upadhye, IR Contact OfficerView
Samiran Das, Executive Vice President Head - FTO and GGPMView
Sauri Gudlavalleti, Global Head of Integrated Product Development OrganizationView
YUGANDHAR PUVVALA, Global Head of Supply ChainView
Amit Biswas, Executive Vice President - Integrated Product DevelopmentView
Ravi Bhoothalingam, Non-Executive Independent DirectorView
Alok Sonig, Senior Vice President & India Business Head (Generics)View
Allan Oberman, Non-Executive Independent DirectorView
J Ramachandran, Executive Vice President-Management Systems and Corporate InitiativesView
Prasad Menon, Lead Non-Executive Independent DirectorView
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)View
Abhijit Mukherjee, COOView
Anil Namboodiripad, Global Head of Proprietary ProductsView
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCREView
SANJAY SHARMA, Global Head of ManufacturingView
Shikha Sharma, Non-Executive Independent DirectorView
Sridar Iyengar, Non-Executive Independent DirectorView
Ganadhish Kamat, Executive Vice President and Global Head-QualityView
Sripada Chandrasekhar, President, Global Head of HR and Member of Management CouncilView
Omkar Goswami, Non-Executive Independent DirectorView
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAIView
Kalpana Morparia, Non-Executive Independent DirectorView
Bharat Doshi, Non-Executive Independent DirectorView
J Moreau, Non-Executive Independent DirectorView
Raymond Vre, Global Head of BiologicsView
Raghav Chari, Senior Vice President - Proprietary ProductsView
Bruce Carter, Non-Executive Independent DirectorView
Saunak Savla, IR Contact OfficerView
Ashok Ganguly, Non-Executive Independent DirectorView
Umang Vohra, Executive Vice President Head - North America GenericsView
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)View
Cartikeya Reddy, Senior Vice President Head - BiologicsView
Anupam Puri, Non-Executive Independent DirectorView
Archana Bhaskar, Chief Human Resource OfficerView
Deepak Sapra, Global Head of PSAIView

Stock Performance Indicators

Current Sentiment - RDY

Dr Reddys Laboratories Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Dr Reddys Laboratories Ltd. What is your opinion about investing in Dr Reddys Laboratories Ltd? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 100 shares of
a day ago
Traded for 30.71
Purchased over 500 shares of
a day ago
Traded for 3.54
Purchased over 100 shares of
a day ago
Traded for 30.71
Purchased over 40 shares of
a day ago
Traded for 66.38
Purchased over 70 shares of
a day ago
Traded for 43.18
Additionally, take a look at Your Equity Center. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.